Global Cannabis Market Hits $28 Billion: The Numbers Behind the Green Economy

A $28 Billion Market: Understanding the Scale of Legal Cannabis

Published July 14, 2022 — By Ann Karim, Senior Cannabis Editor

The North American Engine of Legal Cannabis

The global legal cannabis market of 2022 was overwhelmingly a North American story. The United States — with recreational cannabis legal in 21 states and medical cannabis programs in the majority of states — and Canada, which had federally legalized recreational cannabis in 2018, together accounted for approximately 90% of global legal cannabis retail sales. This concentration reflected both the scale of North American consumption and the simple fact that most other major consumer markets remained either fully prohibited or limited to medical-only frameworks with small patient populations and restricted product ranges.

Within North America, the US legal market was significantly larger than Canada’s despite Canada’s earlier federal legalization. The reason was scale: Canada has 38 million people, while the US has over 330 million, and even with cannabis legal only in certain states, the addressable US market vastly exceeded Canada’s. California alone — the world’s fifth largest economy — had an annual legal cannabis market estimated at over $5 billion. Individual US state markets like Colorado, Washington, and Illinois each generated more legal cannabis revenue than Canada’s entire national market in certain years, illustrating the eventual prize represented by potential US federal legalization that would open all 50 states to full commercial cannabis activity.

The investment community recognized this trajectory even as stock prices for cannabis multistate operators and Canadian licensed producers were volatile. The long-term bull case for cannabis investment rested on the assumption that federal legalization would eventually unlock the full US market, eliminate the banking and tax disadvantages created by Schedule I classification, and allow cannabis companies to list on major US stock exchanges and access capital markets on the same terms as other consumer goods companies. These factors — rather than current profitability — drove cannabis company valuations throughout 2021 and into 2022 before interest rate changes and capital market conditions brought sector-wide valuation corrections.

“The cannabis market is not just large — it is structurally different from any previous consumer product market that has emerged from prohibition. The regulatory complexity is enormous, but so is the eventual opportunity.” — Cannabis industry analyst, 2022

Europe: The Fastest-Growing Region

While North America dominated the global market by volume, Europe represented the most dynamic growth story in 2022. Medical cannabis programs had been expanding across EU member states: Germany since 2017, Italy and Poland developing medical frameworks, the Netherlands authorizing cultivated supply, Portugal with its decriminalization environment, and smaller markets like Malta creating new legal frameworks. Europe’s total legal cannabis market was a fraction of North America’s in absolute terms but was growing at substantially higher rates from a lower base.

The European growth story was primarily medical at this stage, but the December 2021 German coalition commitment to recreational legalization and the growing acceptance of adult-use reform across European political parties suggested that recreational cannabis revenues would become a significant European market component before the end of the decade. Market research firms that included European recreational projections in their 2030 forecasts produced significantly higher global total addressable market numbers than those focused only on current legal frameworks. The difference between a medical-only European market and a recreational European market was measured in tens of billions of dollars of projected annual revenue.

Investment Trends and Market Maturation

The 2022 global cannabis market data reflected not just sales figures but the maturation of the industry’s investment landscape. The cannabis investment boom of 2018-2021 — characterized by high-flying stock valuations, aggressive multistate expansion, and speculative capital flowing into the sector — gave way in 2022 to a more sobering market environment. Rising interest rates reduced appetite for speculative growth stocks. Several large cannabis multistate operators posted ongoing operating losses as the costs of regulatory compliance, expansion capital, and the Section 280E tax burden constrained profitability.

The investment correction did not indicate a fundamentally flawed market thesis — rather, it reflected the overvaluation of a regulatory transition period. Cannabis companies that built sustainable cost structures, focused on high-revenue state markets with favorable regulatory environments, and invested in brand differentiation tended to weather the 2022 correction better than those that had over-leveraged for rapid geographic expansion. For investors and observers tracking the green economy, the shift from speculative growth to operational discipline was a sign of market maturation rather than market failure, consistent with the evolution of other emerging industries transitioning from their initial boom phase to sustained commercial development.

What Drives Growth: The Structural Factors

Several structural factors underpin the long-term market growth projections that placed the global cannabis market on a trajectory toward $100 billion by 2030. Demographic aging in major consumer markets increases demand for medical cannabis as alternatives to opioids and pharmaceutical pain management. Social acceptance of cannabis use continues to rise across age groups, particularly as the generation that grew up with legalization enters peak earning and spending years. And the ongoing state-by-state and country-by-country expansion of legal frameworks — reflected in the news from Germany, Malta, Maryland, Missouri, and Thailand that defined 2021 and 2022 — keeps adding new legal consumer populations to the addressable global market for regulated cannabis products.